Ongoing opioid litigation, enforcement actions, and increased scrutiny from the DEA have fundamentally reshaped regulatory compliance expectations across the independent pharmacy supply chain. In response, drug distributors and manufacturers are tightening controls and imposing requirements that often go well beyond baseline DEA regulations.
For independent pharmacies, this creates a dual risk:
Losing a distributor relationship can be operationally devastating—sometimes more immediately damaging and threatening to the bottom line than a regulatory action imposed by the DEA.
The good news: many of the same steps that prepare you for a DEA inspection also reduce your risk of being cut off by a distributor. The key is proactively addressing the “red flags” that both entities are watching.
At its core, DEA compliance is straightforward in principle: you must maintain complete accountability for controlled substances throughout their “lifecycle” from purchase to dispensing or disposal.
Both DEA diversion investigators and distributors evaluate your pharmacy through this lens. Their reviews typically include:
They are looking for one thing above all: consistency, completeness, and control.
How well would you do on these factors if an inspection happened today? Ask yourself:
Here’s the positive news: the steps you’ll take to tighten your operations will produce benefits for both DEA and distributor scrutiny, improving your odds of avoiding costly penalties and disastrous contract disruptions.
1. Conduct a Rigorous Records Review: Your documentation is your first line of defense.
Be sure that you regularly:
2. Tighten Physical and Operational Security: Security is not about convenience—it’s about control. When was the last time you:
3. Ensure Staff Competency and Accountability: Compliance is not just about policies and procedures – it’s a consistent focus on learned behaviors. Staff must:
4. Close the Loop on Prior Findings: If you’ve been cited before by the DEA, a distributor, or a state board, you’re under higher scrutiny. Ensure all corrective actions have been implemented and documented. Failing to make or ignoring required changes that you were notified about is, in many ways, worse than being accidentally out of compliance. You’re now facing even harsher penalties.
5. Address Prescriber and Patient Risk: Are you and your staff watching for patterns such as:
These are high-visibility red flags. Ignoring them puts your business at risk. Get them out of your customer base - NOW.
6. Monitor High MME Exposure: Evaluate whether high-dose prescriptions are clinically justified and supported by documentation. Keep meticulous records.
7. Manage Suspicious Orders Proactively: Whether done on purpose or by mistake, suspicious orders (e.g., unusually larger orders, unusual ordering patterns) may mean those orders are frozen and not fulfilled – or could result in a distributor probe that ends in your account being closed.
8. Understand the Impact of Regulatory Actions: Any disciplinary action—DEA or state board—affects how distributors view your risk profile. Get the problems resolved – and document the steps taken to get there.
Independent pharmacies often have fewer resources, rely on limited distributors, and operate with lean staffing. These factors increase risk if not managed proactively.
But TITAN Group is your secret weapon for keeping your business operating, even in the face of greater scrutiny. TITAN Group provides:
With a strong national track record of helping independent pharmacies preserve distributor relationships and survive DEA scrutiny, TITAN provides operational stability.
The pharmacies that succeed in this environment are proactive—not reactive. If you’re unsure where you stand, now is the time to find out. Contact TITAN Group today to learn more about how we can support your success.